Artículo
Comprando el artículo el PDF del mismo podrá ser descargado
Precio 19,34 €
Comprar ahora
array:19 [ "pii" => "S0025775306718863" "issn" => "00257753" "doi" => "10.1157/13084879" "estado" => "S300" "fechaPublicacion" => "2006-02-18" "documento" => "article" "subdocumento" => "fla" "cita" => "Med Clin. 2006;126:217-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2574 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 2074 "PDF" => 493 ] ] "itemSiguiente" => array:15 [ "pii" => "S0025775306718875" "issn" => "00257753" "doi" => "10.1157/13084871" "estado" => "S300" "fechaPublicacion" => "2006-02-18" "documento" => "article" "subdocumento" => "fla" "cita" => "Med Clin. 2006;126:220-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1265 "formatos" => array:3 [ "EPUB" => 5 "HTML" => 705 "PDF" => 555 ] ] "es" => array:7 [ "idiomaDefecto" => true "titulo" => "Elastografía de transición (Fibroscan <span class="elsevierStyleSup">®</span>). un nuevo método no invasivo en la valoración de la fibrosis hepática" "tienePdf" => "es" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "220" "paginaFinal" => "222" ] ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jorge Mendoza, Elena Gómez-Domínguez, Ricardo Moreno-Otero" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Jorge" "apellidos" => "Mendoza" ] 1 => array:2 [ "nombre" => "Elena" "apellidos" => "Gómez-Domínguez" ] 2 => array:2 [ "nombre" => "Ricardo" "apellidos" => "Moreno-Otero" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775306718875?idApp=UINPBA00004N" "url" => "/00257753/0000012600000006/v0_201607111356/S0025775306718875/v0_201607111359/es/main.assets" ] "itemAnterior" => array:15 [ "pii" => "S0025775306718851" "issn" => "00257753" "doi" => "10.1157/13084878" "estado" => "S300" "fechaPublicacion" => "2006-02-18" "documento" => "article" "subdocumento" => "fla" "cita" => "Med Clin. 2006;126:214-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2729 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 2387 "PDF" => 334 ] ] "es" => array:7 [ "idiomaDefecto" => true "titulo" => "Prevención cardiovascular en atención primaria" "tienePdf" => "es" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "214" "paginaFinal" => "216" ] ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pedro González-Santos" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Pedro" "apellidos" => "González-Santos" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775306718851?idApp=UINPBA00004N" "url" => "/00257753/0000012600000006/v0_201607111356/S0025775306718851/v0_201607111359/es/main.assets" ] "es" => array:8 [ "idiomaDefecto" => true "titulo" => "Las estatinas. los hábitos de vida y el tratamiento de la hipercolesterolemia, los tiempos cambian y los criterios también" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "217" "paginaFinal" => "219" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Xavier Pintó" "autores" => array:1 [ 0 => array:4 [ "nombre" => "Xavier" "apellidos" => "Pintó" "email" => array:1 [ 0 => "xpinto@csub.scs.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Unidad de Lípidos y Arteriosclerosis. Servicio de Medicina Interna. Hospital Universitario de Bellvitge. L’Hospitalet de Llobregat. Barcelona. España" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "<span class="elsevierStyleSup">*</span>" "correspondencia" => "Correspondencia: Dr. X. Pintó. Unidad de Lípidos y Arteriosclerosis. Servicio de Medicina Interna. Hospital Universitario de Bellvitge. Avda. Feixa larga s/n. 08907 L’Hospitalet de Llobregat. Barcelona. España. xpinto@csub.scs.es" ] ] ] ] "pdfFichero" => "2v126n06a90151400pdf001.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "Bibliograf¿a" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:34 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res. 2005; 46:179-90." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Steinberg D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1194/jlr.R400012-JLR200" "Revista" => array:6 [ "tituloSerie" => "J Lipid Res. " "fecha" => "2005" "volumen" => "46" "paginaInicial" => "179" "paginaFinal" => "190" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15547293" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras. Informe SEA 2003. Madrid: Ergon; 2003." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras. Informe SEA 2003." "idioma" => "es" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Villar Álvarez F" 1 => "Banegas Banegas JR" 2 => "Donado Campos JM" 3 => "Rodríguez Artalejo F." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "titulo" => "Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras. Informe SEA 2003." "fecha" => "2003" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Introducción a los alimentos funcionales. Med Clin (Barc). 2001; 116:617-9." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Introducción a los alimentos funcionales." "idioma" => "es" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Ros E." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Med Clin (Barc). " "fecha" => "2001" "volumen" => "116" "paginaInicial" => "617" "paginaFinal" => "619" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11412648" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Phytosterols and cholesterol metabolism. Curr Opin Lipidol. 2004; 15:37-41." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Phytosterols and cholesterol metabolism." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Ostlund RE." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Curr Opin Lipidol. " "fecha" => "2004" "volumen" => "15" "paginaInicial" => "37" "paginaFinal" => "41" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15166807" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Extending the cardiovascular benefits of omega-3 fatty acids. Curr Atheroscler Rep. 2005; 7:375-80." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Extending the cardiovascular benefits of omega-3 fatty acids." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Harris WS." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Curr Atheroscler Rep. " "fecha" => "2005" "volumen" => "7" "paginaInicial" => "375" "paginaFinal" => "380" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16105481" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Efectos pleiotrópicos de las estatinas: ¿son relevantes en prevención cardiovascular?. Clin Invest Arterioscler. 2005; 17(Supl 3):31-6." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Efectos pleiotrópicos de las estatinas: ¿son relevantes en prevención cardiovascular?." "idioma" => "es" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Millan J." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Invest Arterioscler. " "fecha" => "2005" "volumen" => "17" "paginaInicial" => "31" "paginaFinal" => "36" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352:20-8." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Braunwald E." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa042378" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2005" "volumen" => "352" "paginaInicial" => "20" "paginaFinal" => "28" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15635109" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Efectos inmunomoduladores de las estatinas. Clin Invest Arterioscler. 2005; 17(Supl 3):1-8." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Efectos inmunomoduladores de las estatinas." "idioma" => "es" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Pintó X." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Invest Arterioscler. " "fecha" => "2005" "volumen" => "17" "paginaInicial" => "1" "paginaFinal" => "8" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Expert Panel on Detection" 1 => "Evaluation" 2 => "and Treatment of High Blood Cholesterol in Adults." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "JAMA. " "fecha" => "2001" "volumen" => "285" "paginaInicial" => "2486" "paginaFinal" => "2497" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11368702" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-39." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:10 [ 0 => "Grundy SM" 1 => "Cleeman JI" 2 => "Merz CN" 3 => "Brewer HB" 4 => "Clark LT" 5 => "Hunninghake DB" 6 => "et-al" 7 => "National Heart" 8 => "Lung" 9 => "and Blood Institute; American College of Cardiology Foundation; American Heart Association." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/01.CIR.0000133317.49796.0E" "Revista" => array:6 [ "tituloSerie" => "Circulation. " "fecha" => "2004" "volumen" => "110" "paginaInicial" => "227" "paginaFinal" => "239" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15249516" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360:23-33." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Heart Protection Study Collaborative Group." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(02)09328-5" "Revista" => array:6 [ "tituloSerie" => "Lancet. " "fecha" => "2002" "volumen" => "360" "paginaInicial" => "23" "paginaFinal" => "33" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12114037" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Fluvastatin reduces cardiac mortality in patients with coronary heart disease. Cardiovasc Drugs Ther. 2004; 18:67-75." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Fluvastatin reduces cardiac mortality in patients with coronary heart disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Ballantyne CM" 1 => "Riegger G" 2 => "Moore N" 3 => "Saia F" 4 => "Serruys PW." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1023/B:CARD.0000025757.14093.e0" "Revista" => array:6 [ "tituloSerie" => "Cardiovasc Drugs Ther. " "fecha" => "2004" "volumen" => "18" "paginaInicial" => "67" "paginaFinal" => "75" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15115905" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495-504." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Intensive versus moderate lipid lowering with statins after acute coronary syndromes." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Cannon CP" 1 => "Braunwald E" 2 => "McCabe CH" 3 => "Rader DJ" 4 => "Rouleau JL" 5 => "Belder R" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa040583" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2004" "volumen" => "350" "paginaInicial" => "1495" "paginaFinal" => "1504" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15007110" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Factores emergentes de riesgo cardiovascular. En: Millán Nuñez-Cortés J., editors. Medicina cardiovascular Arteriosclerosis. Barcelona: Masson; 2005. 457-69." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Factores emergentes de riesgo cardiovascular." "idioma" => "es" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Pintó X" 1 => "Meco JF." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "titulo" => "Factores emergentes de riesgo cardiovascular." "paginaInicial" => "457" "paginaFinal" => "469" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995; 274:1771-4." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Maher VM" 1 => "Brown BG" 2 => "Marcovina SM" 3 => "Hillger LA" 4 => "Zhao XQ" 5 => "Albers JJ." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "JAMA. " "fecha" => "1995" "volumen" => "274" "paginaInicial" => "1771" "paginaFinal" => "1774" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7500507" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352:1425-35." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Intensive lipid lowering with atorvastatin in patients with stable coronary disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "LaRosa JC" 1 => "Grundy SM" 2 => "Waters DD" 3 => "Shear C" 4 => "Barter P" 5 => "Fruchart JC" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa050461" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2005" "volumen" => "352" "paginaInicial" => "1425" "paginaFinal" => "1435" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15755765" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673606693811" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291:1071-80." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Nissen SE" 1 => "Tuzcu EM" 2 => "Schoenhagen P" 3 => "Brown BG" 4 => "Ganz P" 5 => "Vogel RA" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.291.9.1071" "Revista" => array:6 [ "tituloSerie" => "JAMA. " "fecha" => "2004" "volumen" => "291" "paginaInicial" => "1071" "paginaFinal" => "1080" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14996776" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364:685-96." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Colhoun HM" 1 => "Betteridge DJ" 2 => "Durrington PN" 3 => "Hitman GA" 4 => "Neil HA" 5 => "Livingstone SJ" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(04)16895-5" "Revista" => array:6 [ "tituloSerie" => "Lancet. " "fecha" => "2004" "volumen" => "364" "paginaInicial" => "685" "paginaFinal" => "696" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15325833" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361:1149-58." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Sever PS" 1 => "Dahlof B" 2 => "Poulter NR" 3 => "Wedel H" 4 => "Beevers G" 5 => "Caulfield M" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(03)12948-0" "Revista" => array:6 [ "tituloSerie" => "Lancet. " "fecha" => "2003" "volumen" => "361" "paginaInicial" => "1149" "paginaFinal" => "1158" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12686036" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984; 251:365-74." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "The Lipid Research Clinics Coronary Primary Prevention Trial results." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "JAMA. " "fecha" => "1984" "volumen" => "251" "paginaInicial" => "365" "paginaFinal" => "374" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/6361300" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-7." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:8 [ 0 => "West of Scotland Coronary Prevention Study Group" 1 => "Shepherd J" 2 => "Cobbe SM" 3 => "Ford I" 4 => "Isles CG" 5 => "Lorimer AR" 6 => "MacFarlane PW" 7 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199511163332001" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "1995" "volumen" => "333" "paginaInicial" => "1301" "paginaFinal" => "1307" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7566020" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 1979; 90:85-91." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Kannel WB" 1 => "Castelli WP" 2 => "Gordon T." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med. " "fecha" => "1979" "volumen" => "90" "paginaInicial" => "85" "paginaFinal" => "91" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/217290" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360:1623-30." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:8 [ 0 => "Shepherd J" 1 => "Blauw GJ" 2 => "Murphy MB" 3 => "Bollen EL" 4 => "Buckley BM" 5 => "Cobbe SM" 6 => "et-al" 7 => "PROSPER study group." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Lancet. " "fecha" => "2002" "volumen" => "360" "paginaInicial" => "1623" "paginaFinal" => "1630" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12457784" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352:2184-92." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Statins and the risk of colorectal cancer." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Poynter JN" 1 => "Gruber SB" 2 => "Higgins PD" 3 => "Almog R" 4 => "Bonner JD" 5 => "Rennert HS" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa043792" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2005" "volumen" => "352" "paginaInicial" => "2184" "paginaFinal" => "2192" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15917383" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004; 292:331-7." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Wiegman A" 1 => "Hutten BA" 2 => "De Groot E" 3 => "Rodenburg J" 4 => "Bakker HD" 5 => "Buller HR" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.292.3.331" "Revista" => array:6 [ "tituloSerie" => "JAMA. " "fecha" => "2004" "volumen" => "292" "paginaInicial" => "331" "paginaFinal" => "337" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15265847" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study. J Clin Endocrinol Metab. 2005; 90:1942-52." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Hedman M" 1 => "Matikainen T" 2 => "Fohr A" 3 => "Lappi M" 4 => "Piippo S" 5 => "Nuutinen M" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/jc.2004-1541" "Revista" => array:6 [ "tituloSerie" => "J Clin Endocrinol Metab. " "fecha" => "2005" "volumen" => "90" "paginaInicial" => "1942" "paginaFinal" => "1952" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15657370" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation. 2003; 107:3124-8." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Bruckert E" 1 => "Giral P" 2 => "Tellier P." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/01.CIR.0000072345.98581.24" "Revista" => array:6 [ "tituloSerie" => "Circulation. " "fecha" => "2003" "volumen" => "107" "paginaInicial" => "3124" "paginaFinal" => "3128" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12835406" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004; 350:1505-15." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Brousseau ME" 1 => "Schaefer EJ" 2 => "Wolfe ML" 3 => "Bloedon LT" 4 => "Digenio AG" 5 => "Clark RW" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa031766" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med. " "fecha" => "2004" "volumen" => "350" "paginaInicial" => "1505" "paginaFinal" => "1515" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15071125" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005; 365:1389-97." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Van Gaal LF" 1 => "Rissanen AM" 2 => "Scheen AJ" 3 => "Ziegler O" 4 => "Rossner S" 5 => "RIO-Europe Study Group." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(05)66374-X" "Revista" => array:6 [ "tituloSerie" => "Lancet. " "fecha" => "2005" "volumen" => "365" "paginaInicial" => "1389" "paginaFinal" => "1397" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15836887" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Pharmacotherapy for dyslipidemia-current therapies and future agents. Expert Opin Pharmacother. 2003; 11:1901-38." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Pharmacotherapy for dyslipidemia-current therapies and future agents." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Bays H" 1 => "Stein EA." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1517/14656566.2010.494179" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Pharmacother. " "fecha" => "2003" "volumen" => "11" "paginaInicial" => "1901" "paginaFinal" => "1938" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20536295" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002; 30:1280-7." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effects of fibrates on metabolism of statins in human hepatocytes." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Prueksaritanont T" 1 => "Tang C" 2 => "Quiu Y" 3 => "Mu L" 4 => "Subramanian R" 5 => "Lin JH." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Drug Metab Dispos. " "fecha" => "2002" "volumen" => "30" "paginaInicial" => "1280" "paginaFinal" => "1287" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12386136" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and shortterm effects of fenofibrate. Cardiovasc Diabetol. 2005; 4:13." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and shortterm effects of fenofibrate." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Scott R" 1 => "Best J" 2 => "Forder P" 3 => "Taskinen MR" 4 => "Simes J" 5 => "Barter P" 6 => "et-al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1475-2840-4-13" "Revista" => array:5 [ "tituloSerie" => "Cardiovasc Diabetol. " "fecha" => "2005" "volumen" => "4" "paginaInicial" => "13" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16111499" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Planificación del tratamiento de la hipercolesterolemia orientado a la obtención de objetivos. Med Clin (Barc). 2005; 124:108-10." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Planificación del tratamiento de la hipercolesterolemia orientado a la obtención de objetivos." "idioma" => "es" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Masana L" 1 => "Plana N." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Med Clin (Barc). " "fecha" => "2005" "volumen" => "124" "paginaInicial" => "108" "paginaFinal" => "110" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15710098" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib34" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Adaptación española de la guía europea de prevención cardiovascular. Aten Primaria. 2004; 34:427-32." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Adaptación española de la guía europea de prevención cardiovascular." "idioma" => "es" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:8 [ 0 => "Brotons C" 1 => "Royo-Bordonada MA" 2 => "Álvarez-Sala L" 3 => "Armario P" 4 => "Artigas R" 5 => "Conté P" 6 => "et-al" 7 => "Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC)." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Aten Primaria. " "fecha" => "2004" "volumen" => "34" "paginaInicial" => "427" "paginaFinal" => "432" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15546541" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/00257753/0000012600000006/v0_201607111356/S0025775306718863/v0_201607111359/es/main.assets" "Apartado" => array:4 [ "identificador" => "55623" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editorial retrospectivo" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/00257753/0000012600000006/v0_201607111356/S0025775306718863/v0_201607111359/es/2v126n06a90151400pdf001.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775306718863?idApp=UINPBA00004N" ]
Consulte los artículos y contenidos publicados en este medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación
Esté informado en todo momento gracias a las alertas y novedades
Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados
Medicina Clínica, fundada en 1943, es la única publicación semanal de contenido clínico que se edita en España y constituye el máximo exponente de la calidad y pujanza de la medicina española. Son características fundamentales de esta publicación el rigor científico y metodológico de sus artículos, la actualidad de los temas y, sobre todo, su sentido práctico, buscando siempre que la información sea de la mayor utilidad en la práctica clínica. Los contenidos de Medicina Clínica abarcan dos frentes: trabajos de investigación original rigurosamente seleccionados atendiendo a su calidad, originalidad e interés, y trabajos orientados a la formación continuada, encomendados por la revista a autores relevantes (Editoriales, Revisiones, Conferencias clínicas y clínico-patológicas, Diagnóstico y Tratamiento). En estos artículos se ponen al día aspectos de destacado interés clínico o conceptual en la medicina actual. Medicina Clínica es un vehículo de información científica de reconocida calidad, como demuestra su inclusión en los más prestigiosos y selectivos índices bibliográficos del mundo.
Current Contents/Clinical Medicine, Journal Citation Reports, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, MEDES, PASCAL, SCOPUS, ScienceDirect
Ver másEl factor de impacto mide la media del número de citaciones recibidas en un año por trabajos publicados en la publicación durante los dos años anteriores.
© Clarivate Analytics, Journal Citation Reports 2022
SJR es una prestigiosa métrica basada en la idea de que todas las citaciones no son iguales. SJR usa un algoritmo similar al page rank de Google; es una medida cuantitativa y cualitativa al impacto de una publicación.
Ver másSNIP permite comparar el impacto de revistas de diferentes campos temáticos, corrigiendo las diferencias en la probabilidad de ser citado que existe entre revistas de distintas materias.
Ver másMedicina Clínica sigue las recomendaciones para la preparación, presentación y publicación de trabajos académicos en revistas biomédicas
¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?
Are you a health professional able to prescribe or dispense drugs?
Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos